EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Disease-modifying therapies for Alzheimer’s disease: Clinical trial progress and opportunity

Yujie Zhang, Jie Chen, Yanru Li, Bin Jiao, Shilin Luo

Ageing Research Reviews · 2025-01 · 103 · 102595

DOI: 10.1016/j.arr.2024.102595 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Ageing Research Reviews, 2025-01. Verfasst von Yujie Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Xiangya Hospital, Central South University, Changsha 410008, PR China; Xiangya School of Medicine, Central South University,…. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloid beta-Peptides, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 145 Literaturangaben. Gefördert von: Hunan Provincial Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The U.S. Food and Drug Administration (FDA) recently approved lecanemab and donanemab for the treatment of early symptomatic Alzheimer's disease (AD) after their phase III trials reached endpoints. These two anti-amyloid β monoclonal antibodies represent the latest promise of disease-modifying therapy (DMT) for AD, which undoubtedly reignites new hope for DMTs to combat the staggering financial and human costs of AD. However, in addition to these two successful antibodies, there have been enormous efforts to develop DMTs in various aspects to meet the therapeutic requirement of AD. In this review, we delineate the core principles and methodologies of diverse DMTs, covering the advances in clinical trials of drug candidates that either have been discontinued, completed, or are ongoing, as well as brain stimulation and lifestyle interventions. In addition, by overseeing the fate of various candidate molecules, we hope to provide references and ideas for prospective approaches and promising applications of DTMs for AD, particularly in terms of universality and clinical application economics, to optimize efficacy and maximize AD patient benefits in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseAmyloid beta-PeptidesAntibodies, Monoclonal, HumanizedHumansClinical Trials as Topic

Stichwörter der Autor:innen

Alzheimer's diseaseAntibodyClinical trialDisease-modifying therapies

Substanzen

Amyloid beta-PeptideslecanemabdonanemabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Neurology, Xiangya Hospital, Central South University, Changsha 410008, PR China; Xiangya School of Medicine, Central South University, Changsha 410013, PR China.
  • Department of Rehabilitation, Xiangya Boai Rehabilitation Hospital, Changsha 410100, PR China.
  • Department of Neurology, Xiangya Hospital, Central South University, Changsha 410008, PR China; National Clinical Research Center for Geriatric Disorders, Central South University, Changsha 410008, PR China; Engineering…

Förderung

  • Hunan Provincial Natural Science Foundation

Zitieren

APA

Zhang, Y., Chen, J., Li, Y., Jiao, B., & Luo, S. (2025). Disease-modifying therapies for Alzheimer’s disease: Clinical trial progress and opportunity. Ageing Research Reviews, 103, 102595. https://doi.org/10.1016/j.arr.2024.102595

Vancouver

Zhang Y, Chen J, Li Y, Jiao B, Luo S. Disease-modifying therapies for Alzheimer’s disease: Clinical trial progress and opportunity. Ageing Research Reviews. 2025;103:102595. doi:10.1016/j.arr.2024.102595

BibTeX
@article{Zhang2025,
  author = {Zhang, Yujie and Chen, Jie and Li, Yanru and Jiao, Bin and Luo, Shilin},
  title = {Disease-modifying therapies for Alzheimer’s disease: Clinical trial progress and opportunity},
  journal = {Ageing Research Reviews},
  year = {2025},
  volume = {103},
  pages = {102595},
  doi = {10.1016/j.arr.2024.102595}
}
Kostenlos starten →